Horm Metab Res 2011; 43(12): 838-843
DOI: 10.1055/s-0031-1284354
Humans, Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Chemotherapy in Patients with Progressive, Undifferentiated Neuroendocrine Tumors: A Single-Center Experience

T. Deutschbein
1   Department of Endocrinology and Division of Laboratory Research, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
N. Unger
1   Department of Endocrinology and Division of Laboratory Research, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
A. Yuece
1   Department of Endocrinology and Division of Laboratory Research, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
W. Eberhardt
2   Department of Medicine (Cancer Research), West German Tumor Centre, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
T. Gauler
2   Department of Medicine (Cancer Research), West German Tumor Centre, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
H. Lahner
1   Department of Endocrinology and Division of Laboratory Research, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
K. Mann
1   Department of Endocrinology and Division of Laboratory Research, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
S. Petersenn
1   Department of Endocrinology and Division of Laboratory Research, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
› Author Affiliations
Further Information

Publication History

received20 March 2011

accepted 28 June 2011

Publication Date:
11 October 2011 (online)

Abstract

Treatment of patients with undifferentiated and histologically confirmed neuroendocrine tumors (NET) usually includes chemotherapeutic intervention. This retrospective study evaluated the outcome of 2 such chemotherapies. 18 patients (11 males; age 56.2±2.5) with proven progressive disease were enrolled (mean Ki-67 34±5%). Patients were treated from 2005 to 2007 with regimen A (carboplatin, etoposide, paclitaxel), and from 2007 to 2009 with regimen B (cisplatin, etoposide). This change was due to low tolerability of regimen A. The standard imaging procedure was computed tomography. 8 patients underwent treatment with regimen A (mean 3.3±0.7 courses). Due to severe side effects, 3 patients had their therapy prematurely discontinued. The treatment responses of 6 patients who received more than 1 course were: 0% complete response (CR), 17% partial response (PR), 50% stable disease (SD), and 33% progressive disease (PD). The median progression free survival (PFS) was 6.7 months (range 3.2–10.0). In contrast, 12 patients received regimen B (mean 3.8±0.4 courses), and none of them dropped out because of side effects. The overall responses were: 0% CR, 17% PR, 42% SD, and 42% PD. The median PFS was 6.3 months (range 2.8–26.4). The response rates of both regimes were not statistically different. Patients who were treated with regimen B demonstrated comparable PFS and less severe side effects than patients who received regimen A. However, patients need to be aware of the relatively short PFS time. In order to improve therapeutic outcome of patients with progressive undifferentiated NET, new therapeutic approaches and larger multi-center studies are needed.

 
  • References

  • 1 Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26: 3063-3072
  • 2 Solcia E, Kloppel G, Sobin LH (in collaboration with 9 pathologists from 4 countries) Histological typing of endocrine tumours. In: WHO: International Histological Classification of Tumours. Berlin: Springer; 2000. 5 the ed
  • 3 Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
  • 4 Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol 2009; 36: 52-59
  • 5 Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68: 227-232
  • 6 Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufié P, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81: 1351-1355
  • 7 Fjällskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92: 1101-1107
  • 8 Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA.. Carcinoma of unknown primary site: Treatment with 1-h paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997; 15: 2385-2393
  • 9 Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: A Minnie Pearl Cancer Research Network Study. J Clin Oncol 2006; 24: 3548-3554
  • 10 Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
  • 11 Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481
  • 12 Johnson LA, Lavin P, Moertel CG, Weiland L, Dayal YY, Doos WG, Geller SA, Cooper HS, Masse SR, Engstrom PF. Carcinoids: The association of histologic growth pattern and survival. Cancer 1983; 51: 882-889
  • 13 Staren ED, Gould VE, Warren WH, Wool NL, Bines S, Baker J, Bonomi P, Roseman DL, Economou SG. Neuroendocrine carcinomas of the colon and rectum: A clinicopathologic evaluation. Surgery 1988; 104: 1080-1089
  • 14 Rindi G, Bordi C, Rappel S, Larosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: Pathogenesis, pathology, and behavior. World J Surg 1996; 20: 168-172
  • 15 Seitz JF, Perrier H, Giovannini M, Menges C, Fourdan O, Barrière N, Viens P. Cancers neuroendocrines anaplasiques avancés: intérêt de l’association VP16-CDDP. Bull Cancer 1995; 82: 433-434
  • 16 Greco FA, Vaughn WK, Hainsworth JD. Advanced poorly differentiated carcinoma of unknown primary site: Recognition of a treatable syndrome. Ann Intern Med 1986; 104: 547-551
  • 17 van der Gaast A, Verweij J, Henzen-Logmans SC. Carcinoma of unknown primary: Identification of a treatable subset?. Ann Oncol 1990; 1: 119-123
  • 18 Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: Results of a 12-year experience. J Clin Oncol 1992; 10: 912-922
  • 19 Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CS, Fuchs CS. Activity of Sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26: 3403-3410
  • 20 Hainsworth JD, Stroup SL, Greco FA. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung cancer. Cancer 1996; 77: 2458-2463
  • 21 Greco FA, Burris 3rd HA, Erland JB, Gray JR, Kalkmann LA, Schreeder MT, Hainsworth JD. Carcinoma of unknown primary site. Cancer 2000; 89: 2655-2660
  • 22 Rindi G, Arnold R, Bosman FT, Capella C, Klimstra DS, Klöppel G, Komminoth P, Solcia E. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman F, Carneiro F, Hruban R, Theise N. eds WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010: 13-14